Skip to main content
Using longitudinal claims data, this study explores the safety of non-conventional combination targeted therapy in adult

Antoni Chan MD (Prof) synovialjoints

1 year 8 months ago
Using longitudinal claims data, this study explores the safety of non-conventional combination targeted therapy in adults with psoriatic arthritis (PsA). Key findings: - 42,821 PsA patients analyzed; only 1.1% on combination therapy. - Increased risk of serious infections:… https://t.co/Jghmz9lkLd https://t.co/YqwJlTKcEi
RA patients affected by frailty at a younger age
in @VARA frailty associated with lower BMD
But frailty is modifiable!

Jiha Lee JihaRheum

1 year 8 months ago
RA patients affected by frailty at a younger age in @VARA frailty associated with lower BMD But frailty is modifiable! #GeriRheum #ACR24 @RheumNow ABST#2140 https://t.co/BoTGoESB43
Class V #Lupus Nephritis usually takes longer to treat. Stay the course if no contraindications and taper steroids! - Dr

TheDaoIndex KDAO2011

1 year 8 months ago
Class V #Lupus Nephritis usually takes longer to treat. Stay the course if no contraindications and taper steroids! - Dr A Askanase #ACR24 LN Guidelines @RheumNow https://t.co/4BBuAWi2da
Improving the Value of Musculoskeletal Ultrasound in Rheumatology Care #ACR24

MSUS has emerged as a powerful asset in r

Dr. John Cush RheumNow

1 year 8 months ago
Improving the Value of Musculoskeletal Ultrasound in Rheumatology Care #ACR24 MSUS has emerged as a powerful asset in rheumatology, providing a real-time, non-invasive, and cost-effective solution for diagnosing and managing inflammatory arthritis conditions such as RA and PsA.… https://t.co/iH9IZmHhSz https://t.co/am5LoBCdpe
RheumNow’s expanded coverage of #ACR24 is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by

Dr. John Cush RheumNow

1 year 8 months ago
RheumNow’s expanded coverage of #ACR24 is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & its faculty
The findings from ORAL Surveillance Study have been a dominant conversation at recent ACR Convergence, with the seminal findings and subsequent analyses a target of debate. Subsequent post-hoc analyses, follow-up studies, and claims data analyses have been used to further interpret the data, though a clear answer on safety is not certain. A study presented on Sunday reported on a new post-hoc analysis that provides new insights.
A#2528
Hes1/Piezo1 Pathway - role in osteocyte response to mechanical stimulus
Yoda1 - Piezo1 agonist shown to help fx h

Eric Dein ericdeinmd

1 year 8 months ago
A#2528 Hes1/Piezo1 Pathway - role in osteocyte response to mechanical stimulus Yoda1 - Piezo1 agonist shown to help fx healing in mice Piezo1 decrease in GIOP Basic sci research shows activation of pathway promotes mechanical stress response, decr GIOP #ACR24 @RheumNow
Does adding a Clofutriben (HSD-1 inhibitor) w/ prednisone minimize the risks of steroid toxicities in #PMR patients?

V

Akhil Sood MD AkhilSoodMD

1 year 8 months ago
Does adding a Clofutriben (HSD-1 inhibitor) w/ prednisone minimize the risks of steroid toxicities in #PMR patients? VS placebo, PMR patients who received Clofutriben + Prednisone had substantial reductions in bone, lipid, and glycemic control parameters @RheumNow #ACR24
Late-Breaking Abstract L07

The CLASS Project introduces new global classification criteria for Anti-Synthetase Syndrom

Antoni Chan MD (Prof) synovialjoints

1 year 8 months ago
Late-Breaking Abstract L07 The CLASS Project introduces new global classification criteria for Anti-Synthetase Syndrome (ASSD). Using the gold standard dataset, the key findings were: ✅ Definite ASSD: Sensitivity 94.3%, Specificity 99.7% ✅ Probable ASSD: Sensitivity 97.5%,… https://t.co/PtciIMTSsu https://t.co/jvJv2VNvHx
The 🫀is muscle‼️

💥From the maestro herself @JuliePaikMD underscores why cardiac involvement in myositis can't

Caoilfhionn Connolly CaoilfhionnMD

1 year 8 months ago
The 🫀is muscle‼️ 💥From the maestro herself @JuliePaikMD underscores why cardiac involvement in myositis can't be overlooked. 🔥Crucial insights with major implications for patient care and outcomes #acr24 @RheumNow @HopkinsMedicine @jhrheumatology https://t.co/mw6BvkdF2w
Does vasculitis flare with checkpoint inhibitors?

@MDAndersonNews experience:
17 stable pts
4 pts flared - all able to

David Liew drdavidliew

1 year 8 months ago
Does vasculitis flare with checkpoint inhibitors? @MDAndersonNews experience: 17 stable pts 4 pts flared - all able to be controlled (i.e. 13 didn't flare) Encouragement that stable vasculitis pts that need ICI should get them! #ACR24 ABST1986 @RheumNow https://t.co/jO4w3HWBMd
A#2529
Disparities in JIA
Outcome documentation, best practices, access to at-risk pts, agency and access
- outcomes ini

Eric Dein ericdeinmd

1 year 8 months ago
A#2529 Disparities in JIA Outcome documentation, best practices, access to at-risk pts, agency and access - outcomes initially appeared to worsen - reflection of better documentation Improvement driven by pt global scores Disparity gap closed by 17% #ACR24 @RheumNow https://t.co/oOxs0jIvBK
Risks for HCQ cardiotoxicity:
👉>5 yrs use
👉>5 mg/kg/d (cumulative dose >500,000 mg)
👉CKD
👉use NSA

TheDaoIndex KDAO2011

1 year 8 months ago
Risks for HCQ cardiotoxicity: 👉>5 yrs use 👉>5 mg/kg/d (cumulative dose >500,000 mg) 👉CKD 👉use NSAID 👉preexisting heart dz 👉presence of ocular, derm, SkM toxicity - Dr M Garschik #ACR24 @rheumnow https://t.co/LFobgls4jm
A#2530
ANA reactive CD4 cells: elevated B cell help activation in SjD
Unique autoreactive T cell cluster in SSc shows CD

Eric Dein ericdeinmd

1 year 8 months ago
A#2530 ANA reactive CD4 cells: elevated B cell help activation in SjD Unique autoreactive T cell cluster in SSc shows CD4+ TRAIL+ IFN type I - unique to SSc Leads to decrease activation of APCs, decrease CD4 T effector fxn @RheumNow #ACR24 https://t.co/4JnA3SpVM8
×